MedPath

A prospetctive observational study to elucidate the safty and efficacy of GLP-1 analogue treatment for non-alcoholic steatohepatitis patients with type2 diabetes mellitus

Not Applicable
Recruiting
Conditions
ASH patients with type2 diabetes mellitus who have indication for GLP-1 analogue treatment.
Registration Number
JPRN-UMIN000004512
Lead Sponsor
Mitsui Memorial Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1.Patinets who have history of HBV or HCV infection, and auto-immune hepatitis. 2.Patients who take alcohol more than 20g/day as 100% ethanol. 3.Patients who have renal dysfunction (Cre over 2.0 mg/dl or eGFR less than 30 mL/min). 4.Patients who have platelet counts less than 50,000/micro-litter or prothrombin activity less than 50%. 5.Patients who have history of pancreatitis. 6.Patients who are treated with other clinical trial medicine. 7.Patients who have malignancy. 8.Patients who are judged no indication by whome resposible for this study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Imprpvment of the value of transaminase and NAFLD activity score.
Secondary Outcome Measures
NameTimeMethod
Imprpvment of the value of fasting blood sugar, HbA1c, and fasting blood concentration of insulin. Imprpvment of body weight, visveral fat areas, and fatty liver.
© Copyright 2025. All Rights Reserved by MedPath